Exelixis Inc. late Wednesday priced its offering of 15 million shares at $11 per share.
The South San Francisco biotech cancer drug developer (NASDAQ: EXEL) also said it would grant underwriters of the offering a 30-day option to buy up to an additional 2.25 million shares.
In all, the offering, which could close by March 15, would gross $165 million. Exelixis would net about $155.9 million.
No comments:
Post a Comment